Results 51 to 60 of about 68,398 (251)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto +12 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the diagnostic accuracy of glial fibrillary acidic protein (GFAP) measured in dried plasma spots versus conventional plasma‐ and serum‐GFAP testing for assessment of disease severity in aquaporin‐4 immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4‐IgG+ NMOSD).
Felix Wohlrab +19 more
wiley +1 more source
Anti-CD20 monoclonal antibodies: historical and future perspectives
Haematologica, 2009 Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been
Lim, Sean H. +5 more
openaire +4 more sources
Rheumatologic Manifestations of Patients With Type B Insulin Resistance
Arthritis Care &Research, EarlyView.Objective The objectives of this study were to identify laboratory and clinical features associated with type B insulin resistance (TBIR), a rare condition caused by autoantibodies that inhibit the insulin receptor, most frequently occurring in the setting of systemic lupus erythematosus (SLE), and to increase awareness of this rare, life‐threatening ...
S. Amara Ogbonnaya +4 more
wiley +1 more source
Ocrelizumab-Induced Severe Colitis
Case Reports in Gastrointestinal Medicine, 2020 We report a case of severe ocrelizumab (anti-CD20 monoclonal antibody) induced colitis in a 43-year-old woman with multiple sclerosis leading to total colectomy after failing medical therapy.
Hsing Hwa Lee +3 more
doaj +1 more source
Clinical & Translational Immunology, 2022 Objectives Anti‐CD20 monoclonal antibody therapy rapidly depletes > 95% of CD20+ B cells from the circulation. B‐cell depletion is an effective treatment for autoimmune disease and B‐cell malignancies but also increases the risk of respiratory tract ...
Giuseppe Ercoli +6 more
doaj +1 more source
The future of anti-CD20 monoclonal antibodies: are we making progress? [PDF]
Blood, 2011 AbstractThe anti-CD20 monoclonal antibody (mAb) rituximab has revolutionized the treatment of B-cell malignancies. This unprecedented success has not only substantially changed the mindset of the clinical community about the ability of mAb to improve outcomes but has catalyzed the interest in the pharmaceutical industry to develop the next generation ...
Alduaij, Waleed +1 more
openaire +2 more sources
From Payload‐First Toward Dual‐Mechanism Antibody–Drug Conjugates
Advanced Materials, EarlyView.Conjugation converts potent antibodies into underexposed carriers. This perspective defines the antibody exposure deficit and maps a mechanism‐first design space from payload‐first to antibody‐first ADC architectures, integrating DAR, linker chemistry, and Fc engineering to guide rational design of constructs that balance targeted cytotoxicity with ...
Xavier Pivot +3 more
wiley +1 more source
Radiolabeling and biodistribution of monoclonal antibody (MAb) anti-CD20 with iodine-131
Brazilian Archives of Biology and Technology, 2005 Radioactive isotopes of iodine, mainly iodine-131 have been broadly used in many monoclonal antibody radioiodination settings, employing different methods.
Akinkunmi Ganiyu Akanji +4 more
doaj +1 more source
Annals of Neurology, EarlyView.Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello +20 more
wiley +1 more source